Gilead’s Phase II study showed 99% HCV cure rates
26 April 2017 | By Niamh Marriott, Junior Editor
Gilead Sciences’ Phase II studies demonstrated HCV cure rates of 99% in children, and 100% in patients co-infected with HCV and hepatitis B virus...
List view / Grid view
News
RedHill Biopharma enrols last patient in Phase II irritable bowel syndrome trial
26 April 2017 | By Niamh Marriott, Junior Editor
RedHill Biopharma has enrolled the last patient in the Phase II study with Bekinda for the treatment of diarrhoea-predominant irritable bowel syndrome...
BioMarin receives positive CHMP opinion for fatal brain disorder treatment in children
26 April 2017 | By Niamh Marriott, Junior Editor
CHMP has adopted a positive opinion for the company's MAA for Brineura to treat children with Neuronal Ceroid Lipofuscinosis Type 2 disease...
Sandoz proposed biosimilars recommended for EU approval
25 April 2017 | By Niamh Marriott, Junior Editor
The Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions, separately recommending the approval of both Sandoz's (a Novartis division) biosimilar rituximab and biosimilar etanercept in Europe, to treat the same indications as their respective reference medicines.
Pfizer’s Phase III study to treat hospital-acquired pneumonia a success
25 April 2017 | By Niamh Marriott, Junior Editor
Pfizer's results show patients diagnosed with hospital-acquired pneumonia (HAP) treated with Zavicefta or Meropenem experienced comparable rates of cure...
FDA allows novel inhaled lung cancer treatment to commence clinical trials
25 April 2017 | By Niamh Marriott, Junior Editor
North Carolina based Biomarck Pharmaceuticals has received FDA allowance to begin human trials for their patented compound BIO-11006, for adults with lung cancer.
BMS Phase II study in non-alcoholic steatohepatitis a success
24 April 2017 | By Niamh Marriott, Junior Editor
BMS-986036 is a pegylated analogue of human fibroblast growth factor 21, a key regulator of metabolism. In preclinical models of non-alcoholic steatohepatitis (NASH), BMS-986036 improved steatosis, inflammation, hepatocyte ballooning, and fibrosis.
AbbVie’s HCV/ compensated cirrhosis drug achieved 99% SVR12 rate
24 April 2017 | By Niamh Marriott, Junior Editor
AbbVie announced that 99% (145/146) of chronic hepatitis C virus (HCV) infected patients with genotype and compensated cirrhosis (Child-Pugh A)...
Solidsoft Reply to operate the Irish National Medicine Verification System
24 April 2017 | By Niamh Marriott, Junior Editor
After Danish and Swedish, Solidsoft Reply has signed an agreement to implement and operate the Irish National Medicines Verification System...
Allergan partners with TARGET PharmaSolutions to advance NASH research
21 April 2017 | By Niamh Marriott, Junior Editor
Allergan will collaborate with TARGET PharmaSolutions, a clinical data company focused on real world evidence, on its TARGET-NASH study.
Ingenza enjoys success at the Made in Scotland awards
21 April 2017 | By Ingenza
Edinburgh-based Ingenza is celebrating after being named the Innovator of the Year at the 2017 Made in Scotland awards, held at the Glasgow Science Centre on the 19th of April...
Rainin TerraRack™ benefits cell differentiation studies
21 April 2017 | By METTLER TOLEDO
METTLER TOLEDO’s Rainin TerraRack™ pipette tip racks are proving advantageous for the University of Glasgow’s Centre for Cell Engineering, where scientists are investigating cell differentiation and behavior on a variety of materials...
Cannabis-based medicine may cut number of epilepsy seizures by half
21 April 2017 | By Niamh Marriott, Junior Editor
Taking cannabidiol may cut seizures in half for some children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy...
Targovax initiates clinical immunotherapy trial to treat RAS-mutated cancer
20 April 2017 | By Niamh Marriott, Junior Editor
Targovax has recruited the first patient in an exploratory Phase Ib clinical trial of TG02 in patients with locally recurrent RAS-mutated rectal cancer...
NIH study shows Novartis drug eltrombopag improves responses in severe aplastic anemia
20 April 2017 | By Niamh Marriott, Junior Editor
Novartis demonstrated that 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved complete response at six months when treated...
